Selected research
Industry Research
Formulation Development CDMO Industry Research Report 2026
Market perspective
The global Formulation Development CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Formulation Development CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Formulation Development CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Formulation Development CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Formulation Development CDMO include Lonza, Ascendia Pharmaceutical Solutions, Catalent, Cambrex, Serán Bioscience, Singota Solutions, Adragos Pharma, Meribel Pharma and Eurofins CDMO, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Formulation Development CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Formulation Development CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Formulation Development CDMO Market by Company
Lonza
Ascendia Pharmaceutical Solutions
Catalent
Cambrex
Serán Bioscience
Singota Solutions
Adragos Pharma
Meribel Pharma
Eurofins CDMO
Skyepharma
Siegfried Group
Recipharm
CordenPharma
Thermo Fisher Scientific
Samsung Biologics
AGC Biologics
WuXi AppTec
Pharmaron
Asymchem
Huahai Pharma
Nipro Pharma
CMIC Group
Hovione
Formulation Development CDMO Segment by Type
Oral Solid Dosage Forms
Injectable Dosage Forms
Transdermal Dosage Forms
Others
Formulation Development CDMO Segment by Application
Small molecule chemical drugs
Biologics
Cell and gene therapy products
Others
Formulation Development CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Formulation Development CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Formulation Development CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Formulation Development CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Formulation Development CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Solid Dosage Forms
- Injectable Dosage Forms
- Transdermal Dosage Forms
- Others
Applications
- Small molecule chemical drugs
- Biologics
- Cell and gene therapy products
- Others
Companies covered
- Lonza
- Ascendia Pharmaceutical Solutions
- Catalent
- Cambrex
- Serán Bioscience
- Singota Solutions
- Adragos Pharma
- Meribel Pharma
- Eurofins CDMO
- Skyepharma
- Siegfried Group
- Recipharm
- CordenPharma
- Thermo Fisher Scientific
- Samsung Biologics
- AGC Biologics
- WuXi AppTec
- Pharmaron
- Asymchem
- Huahai Pharma
- Nipro Pharma
- CMIC Group
- Hovione
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Formulation Development CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral Solid Dosage Forms
- 2.2.3 Injectable Dosage Forms
- 2.2.4 Transdermal Dosage Forms
- 2.2.5 Others
- 2.3 Formulation Development CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Small molecule chemical drugs
- 2.3.3 Biologics
- 2.3.4 Cell and gene therapy products
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Formulation Development CDMO Breakdown Data by Type
- 3.1 Global Formulation Development CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Formulation Development CDMO Forecasted Market Size by Type (2027-2032)
4 Formulation Development CDMO Breakdown Data by Application
- 4.1 Global Formulation Development CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Formulation Development CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Formulation Development CDMO Market Perspective (2021-2032)
- 5.2 Global Formulation Development CDMO Growth Trends by Region
- 5.2.1 Global Formulation Development CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Formulation Development CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Formulation Development CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Formulation Development CDMO Market Dynamics
- 5.3.1 Formulation Development CDMO Industry Trends
- 5.3.2 Formulation Development CDMO Market Drivers
- 5.3.3 Formulation Development CDMO Market Challenges
- 5.3.4 Formulation Development CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Formulation Development CDMO Players by Revenue
- 6.1.1 Global Top Formulation Development CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Formulation Development CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Formulation Development CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Formulation Development CDMO Head Office and Area Served
- 6.4 Global Formulation Development CDMO Players, Product Type & Application
- 6.5 Global Formulation Development CDMO Manufacturers Established Date
- 6.6 Global Formulation Development CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Formulation Development CDMO Market Size (2021-2032)
- 7.2 North America Formulation Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Formulation Development CDMO Market Size by Country (2021-2026)
- 7.4 North America Formulation Development CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Formulation Development CDMO Market Size (2021-2032)
- 8.2 Europe Formulation Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Formulation Development CDMO Market Size by Country (2021-2026)
- 8.4 Europe Formulation Development CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Formulation Development CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Formulation Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Formulation Development CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Formulation Development CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Formulation Development CDMO Market Size (2021-2032)
- 10.2 South America Formulation Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Formulation Development CDMO Market Size by Country (2021-2026)
- 10.4 South America Formulation Development CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Formulation Development CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Formulation Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Formulation Development CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Formulation Development CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lonza
- 12.1.1 Lonza Company Information
- 12.1.2 Lonza Business Overview
- 12.1.3 Lonza Revenue in Formulation Development CDMO Business (2021-2026)
- 12.1.4 Lonza Formulation Development CDMO Product Portfolio
- 12.1.5 Lonza Recent Developments
- 12.2 Ascendia Pharmaceutical Solutions
- 12.2.1 Ascendia Pharmaceutical Solutions Company Information
- 12.2.2 Ascendia Pharmaceutical Solutions Business Overview
- 12.2.3 Ascendia Pharmaceutical Solutions Revenue in Formulation Development CDMO Business (2021-2026)
- 12.2.4 Ascendia Pharmaceutical Solutions Formulation Development CDMO Product Portfolio
- 12.2.5 Ascendia Pharmaceutical Solutions Recent Developments
- 12.3 Catalent
- 12.3.1 Catalent Company Information
- 12.3.2 Catalent Business Overview
- 12.3.3 Catalent Revenue in Formulation Development CDMO Business (2021-2026)
- 12.3.4 Catalent Formulation Development CDMO Product Portfolio
- 12.3.5 Catalent Recent Developments
- 12.4 Cambrex
- 12.4.1 Cambrex Company Information
- 12.4.2 Cambrex Business Overview
- 12.4.3 Cambrex Revenue in Formulation Development CDMO Business (2021-2026)
- 12.4.4 Cambrex Formulation Development CDMO Product Portfolio
- 12.4.5 Cambrex Recent Developments
- 12.5 Serán Bioscience
- 12.5.1 Serán Bioscience Company Information
- 12.5.2 Serán Bioscience Business Overview
- 12.5.3 Serán Bioscience Revenue in Formulation Development CDMO Business (2021-2026)
- 12.5.4 Serán Bioscience Formulation Development CDMO Product Portfolio
- 12.5.5 Serán Bioscience Recent Developments
- 12.6 Singota Solutions
- 12.6.1 Singota Solutions Company Information
- 12.6.2 Singota Solutions Business Overview
- 12.6.3 Singota Solutions Revenue in Formulation Development CDMO Business (2021-2026)
- 12.6.4 Singota Solutions Formulation Development CDMO Product Portfolio
- 12.6.5 Singota Solutions Recent Developments
- 12.7 Adragos Pharma
- 12.7.1 Adragos Pharma Company Information
- 12.7.2 Adragos Pharma Business Overview
- 12.7.3 Adragos Pharma Revenue in Formulation Development CDMO Business (2021-2026)
- 12.7.4 Adragos Pharma Formulation Development CDMO Product Portfolio
- 12.7.5 Adragos Pharma Recent Developments
- 12.8 Meribel Pharma
- 12.8.1 Meribel Pharma Company Information
- 12.8.2 Meribel Pharma Business Overview
- 12.8.3 Meribel Pharma Revenue in Formulation Development CDMO Business (2021-2026)
- 12.8.4 Meribel Pharma Formulation Development CDMO Product Portfolio
- 12.8.5 Meribel Pharma Recent Developments
- 12.9 Eurofins CDMO
- 12.9.1 Eurofins CDMO Company Information
- 12.9.2 Eurofins CDMO Business Overview
- 12.9.3 Eurofins CDMO Revenue in Formulation Development CDMO Business (2021-2026)
- 12.9.4 Eurofins CDMO Formulation Development CDMO Product Portfolio
- 12.9.5 Eurofins CDMO Recent Developments
- 12.10 Skyepharma
- 12.10.1 Skyepharma Company Information
- 12.10.2 Skyepharma Business Overview
- 12.10.3 Skyepharma Revenue in Formulation Development CDMO Business (2021-2026)
- 12.10.4 Skyepharma Formulation Development CDMO Product Portfolio
- 12.10.5 Skyepharma Recent Developments
- 12.11 Siegfried Group
- 12.11.1 Siegfried Group Company Information
- 12.11.2 Siegfried Group Business Overview
- 12.11.3 Siegfried Group Revenue in Formulation Development CDMO Business (2021-2026)
- 12.11.4 Siegfried Group Formulation Development CDMO Product Portfolio
- 12.11.5 Siegfried Group Recent Developments
- 12.12 Recipharm
- 12.12.1 Recipharm Company Information
- 12.12.2 Recipharm Business Overview
- 12.12.3 Recipharm Revenue in Formulation Development CDMO Business (2021-2026)
- 12.12.4 Recipharm Formulation Development CDMO Product Portfolio
- 12.12.5 Recipharm Recent Developments
- 12.13 CordenPharma
- 12.13.1 CordenPharma Company Information
- 12.13.2 CordenPharma Business Overview
- 12.13.3 CordenPharma Revenue in Formulation Development CDMO Business (2021-2026)
- 12.13.4 CordenPharma Formulation Development CDMO Product Portfolio
- 12.13.5 CordenPharma Recent Developments
- 12.14 Thermo Fisher Scientific
- 12.14.1 Thermo Fisher Scientific Company Information
- 12.14.2 Thermo Fisher Scientific Business Overview
- 12.14.3 Thermo Fisher Scientific Revenue in Formulation Development CDMO Business (2021-2026)
- 12.14.4 Thermo Fisher Scientific Formulation Development CDMO Product Portfolio
- 12.14.5 Thermo Fisher Scientific Recent Developments
- 12.15 Samsung Biologics
- 12.15.1 Samsung Biologics Company Information
- 12.15.2 Samsung Biologics Business Overview
- 12.15.3 Samsung Biologics Revenue in Formulation Development CDMO Business (2021-2026)
- 12.15.4 Samsung Biologics Formulation Development CDMO Product Portfolio
- 12.15.5 Samsung Biologics Recent Developments
- 12.16 AGC Biologics
- 12.16.1 AGC Biologics Company Information
- 12.16.2 AGC Biologics Business Overview
- 12.16.3 AGC Biologics Revenue in Formulation Development CDMO Business (2021-2026)
- 12.16.4 AGC Biologics Formulation Development CDMO Product Portfolio
- 12.16.5 AGC Biologics Recent Developments
- 12.17 WuXi AppTec
- 12.17.1 WuXi AppTec Company Information
- 12.17.2 WuXi AppTec Business Overview
- 12.17.3 WuXi AppTec Revenue in Formulation Development CDMO Business (2021-2026)
- 12.17.4 WuXi AppTec Formulation Development CDMO Product Portfolio
- 12.17.5 WuXi AppTec Recent Developments
- 12.18 Pharmaron
- 12.18.1 Pharmaron Company Information
- 12.18.2 Pharmaron Business Overview
- 12.18.3 Pharmaron Revenue in Formulation Development CDMO Business (2021-2026)
- 12.18.4 Pharmaron Formulation Development CDMO Product Portfolio
- 12.18.5 Pharmaron Recent Developments
- 12.19 Asymchem
- 12.19.1 Asymchem Company Information
- 12.19.2 Asymchem Business Overview
- 12.19.3 Asymchem Revenue in Formulation Development CDMO Business (2021-2026)
- 12.19.4 Asymchem Formulation Development CDMO Product Portfolio
- 12.19.5 Asymchem Recent Developments
- 12.20 Huahai Pharma
- 12.20.1 Huahai Pharma Company Information
- 12.20.2 Huahai Pharma Business Overview
- 12.20.3 Huahai Pharma Revenue in Formulation Development CDMO Business (2021-2026)
- 12.20.4 Huahai Pharma Formulation Development CDMO Product Portfolio
- 12.20.5 Huahai Pharma Recent Developments
- 12.21 Nipro Pharma
- 12.21.1 Nipro Pharma Company Information
- 12.21.2 Nipro Pharma Business Overview
- 12.21.3 Nipro Pharma Revenue in Formulation Development CDMO Business (2021-2026)
- 12.21.4 Nipro Pharma Formulation Development CDMO Product Portfolio
- 12.21.5 Nipro Pharma Recent Developments
- 12.22 CMIC Group
- 12.22.1 CMIC Group Company Information
- 12.22.2 CMIC Group Business Overview
- 12.22.3 CMIC Group Revenue in Formulation Development CDMO Business (2021-2026)
- 12.22.4 CMIC Group Formulation Development CDMO Product Portfolio
- 12.22.5 CMIC Group Recent Developments
- 12.23 Hovione
- 12.23.1 Hovione Company Information
- 12.23.2 Hovione Business Overview
- 12.23.3 Hovione Revenue in Formulation Development CDMO Business (2021-2026)
- 12.23.4 Hovione Formulation Development CDMO Product Portfolio
- 12.23.5 Hovione Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst